We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-12.12%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.23B
AUM Growth
-$138M
Cap. Flow
+$87.1M
Cap. Flow %
7.07%
Top 10 Hldgs %
28.99%
Holding
134
New
17
Increased
54
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
STJ
St Jude Medical
STJ
+$37.8M
2
AET
Aetna Inc
AET
+$26.5M
3
ACHC icon
Acadia Healthcare
ACHC
+$23.1M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$21.1M
5
CHMA
Chiasma, Inc. Common Stock
CHMA
+$13M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$42.2M
2
HUM icon
Humana
HUM
+$25.2M
3
THOR
THORATEC CORPORATION
THOR
+$24.5M
4
BHC icon
Bausch Health
BHC
+$17.9M
5
MCK icon
McKesson
MCK
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 76.04%
2 Financials 3.43%
3 Technology 0.48%
4 Industrials 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
51
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$8.55M 0.69%
210,000
+57,500
+38% +$3.31M
IDXX icon
52
Idexx Laboratories
IDXX
$46.2B
$8.35M 0.68%
112,500
+1,500
+1% +$107K
KDNY
53
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$8.04M 0.65%
83,000
+13,000
+19% +$1.55M
JUNO
54
DELISTED
Juno Therapeutics, Inc.
JUNO
$8.02M 0.65%
197,001
+1
+0% +$44
PEN icon
55
Penumbra
PEN
$12.8B
$7.82M 0.63%
+195,000
New +$7.89M
GWPH
56
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$7.81M 0.63%
85,500
+12,250
+17% +$1.36M
ACHN
57
DELISTED
Achillion Pharmaceuticals
ACHN
$7.77M 0.63%
1,125,000
+25,000
+2% +$204K
THOR
58
DELISTED
THORATEC CORPORATION
THOR
$7.59M 0.62%
120,000
-412,500
-77% -$24.5M
WX
59
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
$7.56M 0.61%
175,000
+7,000
+4% +$295K
VRTX icon
60
Vertex Pharmaceuticals
VRTX
$126B
$7.52M 0.61%
72,250
+4,250
+6% +$546K
ITCI
61
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.21M 0.59%
+180,000
New +$5.87M
DERM
62
DELISTED
Dermira, Inc.
DERM
$7M 0.57%
300,001
+50,000
+20% +$1.21M
PCRX icon
63
Pacira BioSciences
PCRX
$997M
$6.91M 0.56%
168,000
+100,000
+147% +$6.12M
JAZZ icon
64
Jazz Pharmaceuticals
JAZZ
$16.7B
$6.84M 0.56%
51,500
+25,500
+98% +$4.39M
INSM icon
65
Insmed
INSM
$28.6B
$6.78M 0.55%
365,000
– –
TBPH icon
66
Theravance Biopharma
TBPH
$877M
$6.62M 0.54%
602,500
+127,500
+27% +$1.62M
GI
67
DELISTED
EndoChoice Holdings, Inc.
GI
$6.54M 0.53%
576,000
+80
+0% +$1.25K
FOLD
68
DELISTED
Amicus Therapeutics
FOLD
$6.37M 0.52%
455,000
+77,500
+21% +$1.22M
ALPN
69
DELISTED
Alpine Immune Sciences Inc
ALPN
$6.34M 0.51%
122,250
-18,840
-13% -$1.24M
OTIC
70
DELISTED
Otonomy, Inc.
OTIC
$5.71M 0.46%
320,800
– –
CHRS icon
71
Coherus Oncology
CHRS
$196M
$5.71M 0.46%
285,000
-249,000
-47% -$7.58M
NVDQ
72
DELISTED
Novadaq Technologies Inc.
NVDQ
$5.63M 0.46%
540,000
– –
XENT
73
DELISTED
Intersect ENT, Inc
XENT
$5.56M 0.45%
237,500
+62,500
+36% +$1.72M
ICPT
74
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$5.39M 0.44%
32,500
– –
MCRB icon
75
Seres Therapeutics
MCRB
$48.9M
$5.33M 0.43%
9,000
-1,361
-13% -$1.11M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Rock Springs Capital Management held 134 positions worth $1.23B, down 10% from $1.37B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $87.1M of net new capital in Q3 2015, opening 17 new positions and adding to 54 existing holdings. Its largest new stake was St Jude Medical: 530,000 shares worth $33.4M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 77% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was THORATEC CORPORATION, an estimated $24.5M trimmed.

  • Rock Springs Capital Management's largest Q3 2015 buy was St Jude Medical: 530,000 shares worth $33.4M.
  • Rock Springs Capital Management added most to Aetna Inc in Q3 2015, an estimated $26.5M increase.
  • Rock Springs Capital Management's biggest Q3 2015 reduction was THORATEC CORPORATION, cutting an estimated $24.5M.
  • Rock Springs Capital Management fully exited Medtronic in Q3 2015, selling an estimated $42.2M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.23B portfolio in Q3 2015.
  • Rock Springs Capital Management opened 17 new positions and closed 13 in Q3 2015.
  • Rock Springs Capital Management's portfolio value fell 10% quarter-over-quarter to $1.23B.

Based on Rock Springs Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.